Researchers who studied the blood of people aged 110 and older found something that runs counter to the standard account of how the immune system ages. Instead of a uniform decline, one rare and powerful population of immune cells had expanded dramatically, with the expansion appearing to begin around age 100.
The cells are CD4 cytotoxic T lymphocytes, a hybrid type that combines the coordinating role of helper T cells with the ability to directly destroy other cells. They make up under 5 percent of T cells in most people. In this study, the median share was about 4 percent among the youngest participants, 9.6 percent among those aged 100 to 109, and 17.6 percent among those aged 110 and older.
The work was published in Cell Reports by a team at the University of Osaka and covered by Nature. The researchers are explicit that they have not shown that these cells cause longevity, and they do not yet know what the cells target.
An Immune Shift That Begins Around 100
“Most of immune aging research has focused on decline,” said Kosuke Hashimoto, a biologist at the University of Osaka, who added that the study suggests the immune system may still selectively adapt even at extreme old age.
The work builds on an earlier finding from the same group, published in 2019, that people past 110 carry unusually high numbers of these cells. The new question was when the expansion starts. Enrolling participants is the hard part, because so few people live that long. Japan has roughly 150 people aged 110 or older.
The study enrolled 28 participants in three groups: eight adults in their 70s, 80s, and 90s, ten centenarians, and ten supercentenarians. Finding the elevated cell counts already present in the 100 to 109 group, not just the oldest, is what moved the timeline earlier.
One detail complicates the neat picture. In this small sample, the highest proportion of these cells was in a participant who had not yet turned 100. The pattern is a trend across groups, not a switch that flips at a birthday.
Cells Cloning Themselves Against an Unknown Target
The second finding concerns what those cells appear to be doing. Every T cell the body produces carries a unique receptor that recognizes a specific threat signal. When a killer T cell meets its target, it clones itself into a line of identical cells that attack.
In the centenarians and supercentenarians, single clonal lines accounted for a large share of all CD4 cytotoxic T cells. In one centenarian’s sample, 53.8 percent of these cells were identical copies of one another. The cells also showed no signs of exhaustion, the worn-out state that typically follows prolonged immune activation. That combination suggests a system responding forcefully to some persistent trigger rather than idling.
The researchers could not identify the trigger. Because they sampled cells circulating in blood, they could not tell which tissues the cells were entering or what they were doing there. To look for clues, they compared receptor sequences from the most common cell lines against a database of CD4 cell receptors. Around 30 sequences matched those found in people with cancer, with lung cancer matches most frequent.
The striking part is that none of the study participants had ever been diagnosed with cancer. In a statement from the university, Hashimoto said the resemblance between these receptor sequences and those in tumor-infiltrating T cells suggests “these cells may help recognize tumors before they become clinically detectable.”
Association, Not a Longevity Recipe
This is where careful reading matters, and the researchers say so themselves. The study does not prove that having more of these cells prevents cancer or extends life. Two other explanations remain open. The cells could be a consequence of surviving to extreme age rather than a cause of it, or both could stem from something else entirely.
The receptor database matches are suggestive, not diagnostic. A shared sequence indicates a possible common target, not confirmation that these cells were fighting tumors.
The sample is also small and geographically narrow. Twenty-eight people, all in Japan, cannot establish that the same pattern holds elsewhere. Studies of extreme longevity face an unavoidable constraint, since the population being studied is extremely small.
The team’s next step is to examine how these cells behave within human tissues rather than in circulating blood, where the question of what they actually do will be answered. Nothing here translates into a supplement, a diet, or a treatment, and no clinical test measures these cells for longevity purposes.
Aging Americans and the Practical Takeaway
The research lands in a country getting significantly older. Pew Research Center analysis of Census Bureau projections estimates the number of Americans aged 100 or older at 101,000 in 2024, a figure projected to more than quadruple to about 422,000 by 2054. Centenarians represented about 0.03 percent of the population and are expected to reach 0.1 percent. The count stood near 2,300 in 1950.
That growth is why basic questions about how immune function changes past 100 matter beyond curiosity. Cancer screening guidelines, vaccination strategy, and treatment decisions for people in their late 90s rest on thin evidence, largely because so few people used to reach those ages.
The useful frame is what this research does and does not offer. It gives a reason to question the assumption that immune aging means only steady decline, and a specific cell population worth studying further. It offers nothing to act on today.
The measures that actually influence cancer risk and healthy aging remain the same: staying current with age-appropriate cancer screening, keeping recommended vaccinations up to date, not smoking, and managing blood pressure, blood sugar, and cholesterol with a clinician. Older adults and caregivers weighing whether to continue screening at advanced ages should discuss that individually with their physician, since the benefit calculation shifts with life expectancy and other conditions.
Whether this work eventually leads to therapies is unknown. Immune cell research has produced real cancer treatments, but the distance between a pattern in 28 people and a usable intervention is long, and most findings at this stage never cross it.
Key Questions Answered
What are CD4 cytotoxic T lymphocytes?
They are an unusual hybrid immune cell that combines features of helper T cells, which coordinate immune responses, and killer T cells, which destroy infected or abnormal cells. They normally make up less than 5 percent of a person’s T cells, and there is growing evidence that they can kill some cancer cells.
What did the study find?
These cells were far more abundant in people aged 100 and older. Median shares were about 4 percent in the youngest group, 9.6 percent among centenarians, and 17.6 percent among people aged 110 and older. Large fractions were single-cell clones and showed no signs of exhaustion.
Does this prove these cells cause long life?
No. The researchers state directly that this has not been proved. The expansion could be a consequence of extreme age rather than a cause, and the study cannot distinguish between the two.
Why do the cancer database matches matter?
Around 30 receptor sequences from study participants matched sequences found in people with cancer, most often lung cancer, even though no participant had ever had cancer. That hints the cells may recognize cancer-related targets, but it does not confirm what they were responding to.
How large was the study?
Twenty-eight participants in Japan: eight in their 70s, 80s, and 90s, ten centenarians, and ten supercentenarians. Supercentenarians are rare enough that Japan has only about 150 people aged 110 or older.
Is there anything a person can do with this information?
Not directly. No supplement, diet, or treatment has been shown to raise these cells, and no clinical test measures them for longevity purposes. Established measures for healthy aging and cancer risk remain screening, vaccination, not smoking, and managing cardiovascular risk factors with a clinician.
